BACKGROUND: In this analysis we use the National Institute on Aging/Alzheimer's Association (NIA/AA) criteria to identify Mild Cognitive Impairment (MCI) in a sample of breast cancer survivors treated with chemotherapy. METHODS: Sixty women ages 39-79 on a prospective clinical trial of donepezil were assessed at baseline using a battery of standardized/validated neurocognitive measures. Cognitive status was adjudicated to identify MCI by a panel of dementia experts. RESULTS: Fifty percent were not cognitively impaired, 43% met the NIA/AA criteria for MCI, 2% had dementia, and 5% could not be classified. DISCUSSION: In this sample, nearly half of breast cancer survivors met the NIA/AA criteria for MCI. We propose these criteria be used to define cancer-related Mild Cognitive Impairment (cMCI), providing a framework for conducting additional studies to further characterize cMCI and identify clinical, imaging, and genetic factors associated with the progression of cMCI to more advanced stages of cognitive impairment.
BACKGROUND: In this analysis we use the National Institute on Aging/Alzheimer's Association (NIA/AA) criteria to identify Mild Cognitive Impairment (MCI) in a sample of breast cancer survivors treated with chemotherapy. METHODS: Sixty women ages 39-79 on a prospective clinical trial of donepezil were assessed at baseline using a battery of standardized/validated neurocognitive measures. Cognitive status was adjudicated to identify MCI by a panel of dementia experts. RESULTS: Fifty percent were not cognitively impaired, 43% met the NIA/AA criteria for MCI, 2% had dementia, and 5% could not be classified. DISCUSSION: In this sample, nearly half of breast cancer survivors met the NIA/AA criteria for MCI. We propose these criteria be used to define cancer-related Mild Cognitive Impairment (cMCI), providing a framework for conducting additional studies to further characterize cMCI and identify clinical, imaging, and genetic factors associated with the progression of cMCI to more advanced stages of cognitive impairment.
Entities:
Keywords:
Breast cancer; Chemotherapy; Dementia; Mild Cognitive Impairment; Quality of life; Survivorship
Authors: Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Bryce B Reeve; Ron D Hays; Jakob B Bjorner; Karon F Cook; Paul K Crane; Jeanne A Teresi; David Thissen; Dennis A Revicki; David J Weiss; Ronald K Hambleton; Honghu Liu; Richard Gershon; Steven P Reise; Jin-shei Lai; David Cella Journal: Med Care Date: 2007-05 Impact factor: 2.983
Authors: Arti Hurria; Carol Rosen; Clifford Hudis; Enid Zuckerman; Katherine S Panageas; Mark S Lachs; Matthew Witmer; Wilfred G van Gorp; Monica Fornier; Gabriella D'Andrea; Mark Moasser; Chau Dang; Catherine Van Poznak; Anju Hurria; Jimmie Holland Journal: J Am Geriatr Soc Date: 2006-06 Impact factor: 5.562
Authors: Sadhna Kohli; Jennifer J Griggs; Joseph A Roscoe; Pascal Jean-Pierre; Christopher Bole; Karen M Mustian; Renae Hill; Kelly Smith; Howard Gross; Gary R Morrow Journal: J Oncol Pract Date: 2007-03 Impact factor: 3.840
Authors: Oscar L Lopez; William J Jagust; Steven T DeKosky; James T Becker; Annette Fitzpatrick; Corinne Dulberg; John Breitner; Constantine Lyketsos; Beverly Jones; Claudia Kawas; Michelle Carlson; Lewis H Kuller Journal: Arch Neurol Date: 2003-10
Authors: Nadine Tchen; Helen G Juffs; Fiona P Downie; Qi-Long Yi; Hanxian Hu; Irene Chemerynsky; Mark Clemons; Michael Crump; Paul E Goss; David Warr; Mary E Tweedale; Ian F Tannock Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2019-04-08
Authors: Christina K Cramer; Neil McKee; L Doug Case; Michael D Chan; Tiffany L Cummings; Glenn J Lesser; Edward G Shaw; Stephen R Rapp Journal: J Neurooncol Date: 2018-11-07 Impact factor: 4.130